BACKGROUND: Friedreich ataxia is an autosomal recessive disorder caused by mutations in the frataxin gene, leading to reduced levels of the mitochondrial protein frataxin. Assays to quantitatively measure frataxin in peripheral blood have been established. To determine the validity of frataxin as a biomarker for clinical trials, we assessed frataxin in clinically affected tissue. METHODS: In 7 patients with Friedreich ataxia, frataxin content was measured in blood and skeletal muscle before and after treatment with recombinant human erythropoietin, applying the electrochemiluminescence immunoassay. RESULTS: We found frataxin content to be correlated in peripheral blood mononuclear cells and skeletal muscle in drug-naive patients with Friedreich ataxia. The correlation of frataxin content in both compartments remained significant after 8 weeks of treatment. Skeletal-muscle frataxin values correlated with ataxia using the Scale for the Assessment and Rating of Ataxia score. CONCLUSIONS: Our results endorse frataxin measurements in peripheral blood cells as a valid biomarker in Friedreich ataxia.
BACKGROUND:Friedreich ataxia is an autosomal recessive disorder caused by mutations in the frataxin gene, leading to reduced levels of the mitochondrial protein frataxin. Assays to quantitatively measure frataxin in peripheral blood have been established. To determine the validity of frataxin as a biomarker for clinical trials, we assessed frataxin in clinically affected tissue. METHODS: In 7 patients with Friedreich ataxia, frataxin content was measured in blood and skeletal muscle before and after treatment with recombinant humanerythropoietin, applying the electrochemiluminescence immunoassay. RESULTS: We found frataxin content to be correlated in peripheral blood mononuclear cells and skeletal muscle in drug-naive patients with Friedreich ataxia. The correlation of frataxin content in both compartments remained significant after 8 weeks of treatment. Skeletal-muscle frataxin values correlated with ataxia using the Scale for the Assessment and Rating of Ataxia score. CONCLUSIONS: Our results endorse frataxin measurements in peripheral blood cells as a valid biomarker in Friedreich ataxia.
Authors: Eppie M Yiu; Geneieve Tai; Roger E Peverill; Katherine J Lee; Kevin D Croft; Trevor A Mori; Barbara Scheiber-Mojdehkar; Brigitte Sturm; Monika Praschberger; Adam P Vogel; Gary Rance; Sarah E M Stephenson; Joseph P Sarsero; Creina Stockley; Chung-Yung J Lee; Andrew Churchyard; Marguerite V Evans-Galea; Monique M Ryan; Paul J Lockhart; Louise A Corben; Martin B Delatycki Journal: J Neurol Date: 2015-04-07 Impact factor: 4.849
Authors: Arnulf H Koeppen; R Liane Ramirez; Alyssa B Becker; Paul J Feustel; Joseph E Mazurkiewicz Journal: J Neuropathol Exp Neurol Date: 2015-02 Impact factor: 3.685
Authors: Charles J Isaacs; Karlla W Brigatti; Olena Kucheruk; Sarah Ratcliffe; Tom Sciascia; Shana E McCormack; Steven M Willi; David R Lynch Journal: Muscle Nerve Date: 2016-08-30 Impact factor: 3.217
Authors: Haiyan Xia; Yun Cao; Xiaoman Dai; Zvonimir Marelja; Di Zhou; Ran Mo; Sahar Al-Mahdawi; Mark A Pook; Silke Leimkühler; Tracey A Rouault; Kuanyu Li Journal: PLoS One Date: 2012-10-17 Impact factor: 3.240
Authors: Heather L Plasterer; Eric C Deutsch; Matthew Belmonte; Elizabeth Egan; David R Lynch; James R Rusche Journal: PLoS One Date: 2013-05-17 Impact factor: 3.240